Capricor Therapeutics, Inc. (NASDAQ: CAPR) Starts Presentation at 29th Annual ROTH Conference
Capricor Therapeutics (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other medical conditions. The company’s lead candidate, CAP-1002, is a cardiac cell therapy that is currently being evaluated for the treatment of heart disease associated with Duchenne muscular dystrophy and myocardial infarction (heart attack). Capricor is exploring the use of CAP-2003, its exosome product candidate in various therapeutic areas including the treatment of ophthalmic disorders. For more information, visit the company’s website at www.capricor.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced…







